Mirogabalin is a preferentially selective a2d-1 ligand and is under development for the treatment of neuropathic pain and pain linked with fibromyalgia. Mirogabalin can be coadministered with metformin in Type 2 diabetes mellitus patients who also have diabetic peripheral neuropathic pain. So, to assess the pharmacokinetics and safety of Mirogabalin and Metformin upon coadministration, J. Dow & colleagues carried a randomized, open-label, single-dose, 3-treatment, 3-crossover, drug-drug interaction study.

A total of 3 treatments separated by a 7-day washout period were given to the eligible participants: a single oral dose of Mirogabalin 15 mg; a single oral dose of Metformin 850 mg; and a single oral dose of Mirogabalin 15 mg plus a single oral dose of Metformin 850 mg. All patients were instructed to administer medications with the meal. To measure Metformin and Mirogabalin pharmacokinetics parameters, serial blood samples were collected before dosing and up to 48 hours after dosing.

A total of Twenty-one healthy Indian men (mean age- 30.4 y) were recruited and finished the study. There was no difference in pharmacokinetic parameters for Mirogabalin and Metformin when administered alone or in combination. No deaths, serious AEs, discontinuations due to AEs, or other clinically relevant AEs were reported in this study.

The findings of this study reveal no drug interaction between Mirogabalin 15 mg and Metformin 850 mg. The coadministration of both drugs is safe and well-tolerated patients.